Abstract:679 Germline mutations of the breast cancer associated gene 1 (BRCA1) have been identified in about 50% of familial breast cancer cases and about 90% of familial breast and ovarian cancers. BRCA1 mutation carriers have a 50 to 80% lifetime risk for developing breast cancer by age 70. Current screening and chemoprevention strategies are suboptimal and consequently some women who are BRCA1 gene carriers elect to prophylactically have their breasts and/or ovaries removed to reduce their risk. Moreover, current chemopreventative drugs often give adverse effects, primarily due to poor specificity of the compounds to mammary tumor tissues. Thus, there is an urgent need to develop safe and effective drugs for the chemoprevention and therapeutic treatment of breast cancer. In the past years, we have created a mouse model carrying a tissue specific disruption of BRCA1 in mammary epithelium. The mutant mice developed mammary tumors at 7-12 months of age. Our analysis revealed that the tumor progression is accompanied by extensive genetic instability and alteration of a number of oncogenes and tumor suppressor genes. Using this animal model and cell lines derived from mammary tumors, we have been studying effects of genistein, green tea, resveratrol, and Poly(ADP-ribose) polymerase (PARP1) inhibitors on BRCA1-associcated tumor formation in order to provide better understand and therapeutic options of BRCA1-assicated breast cancer. Our study indicated that both genistein and resveratrol inhibit growth of tumor cells in culture, in soft agar colony formation and in an allograft nude mouse model. Genistein treated BRCA1 mutant cells were highly polypoid and displayed extensive chromosome abnormalities. Western blot analysis revealed significant increase of CHK2 phosphorylation upon genistein treatment. These observations suggest that genistein induced activation of cell cycle inhibitors may cause cell cycle arrest and cell death, which account for the reduced growth of mutant cells upon the drug treatment. We found that the apoptosis induced by resveratrol in the tumors is accompanied by the activation of NF-kB pathway, and is also partially due to the activation of CHK2 in DNA damage response. Of note, we failed to detect any preventive or therapeutic effects of green tea in both allograft and BRCA1 conditional animals tested. The effectiveness of PARP-1 inhibitors also seemed more specific to BRCA1 mutant embryonic stem cells rather than BRCA1 mutant mammary tumor cells. These data, although promising, remain to be tested in human BRCA1 associated breast cancer cells. Our long-term goal is to decrease cancer risk of BRCA-mutation carriers and find a safe and effective therapeutic method to cure this disease.

The Inhibition and Treatment of Breast Cancer with Poly (Adp-Ribose) Polymerase (PARP-1) Inhibitors.

Potential Biomarkers Of Poly (Adp-Ribose) Polymerase Inhibitors For Cancer Therapy

PARP-1 Inhibitors: Are They the Long-Sought Genetically Specific Drugs for BRCA1/2-associated Breast Cancers?

Differential Immunomodulatory Effect of PARP Inhibition in BRCA1 Deficient and Competent Tumor Cells

Chemoprevention and Therapeutic Treatment of Brca1 Associated Breast Cancer in Conditional Knockout Mice

Selective Inhibition Of Brca2-Deficient Mammary Tumor Cell Growth By Azd2281 And Cisplatin

Abstract 7120: Investigating PARP1 selective inhibitor DSB1559 efficacy in BRCA1-associated triple negative breast cancer

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Effectiveness and Safety of Poly (Adp-Ribose) Polymerase Inhibitors in Cancer Therapy: A Systematic Review and Meta-Analysis

Molecular Pathways: Targeting PARP in Cancer Treatment

Development of Poly(adp-Ribose) Polymerase Inhibitors for Cancertherapy

Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells

PARP Inhibitors for Breast Cancer Treatment

PARP-inhibition reprograms macrophages toward an anti-tumor phenotype

Novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor DDHCB inhibits proliferation of BRCA mutant breast cancer cell in vitro and in vivo through a synthetic lethal mechanism.

CRISPR/Cas9‐mediated Mutagenesis to Validate the Synergy Between PARP1 Inhibition and Chemotherapy in BRCA1‐mutated Breast Cancer Cells

Advances in using PARP inhibitors to treat cancer

Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells